In this edition:
Revised McDonald criteria
HERCULES: tolebrutinib in non-relapsing SPMS
GEMINI 1 & 2: tolebrutinib vs. teriflunomide in relapsing MS
MS-STAT2: simvastatin & disability progression in SPMS
Serious infections with 6 years of ofatumumab
Extension data of frexalimab in relapsing MS
Vitamin D & disease activity after CIS
PIRA in early RRMS/CIS
Humoral immunity after exposure to anti-CD20 therapies
De-escalation treatment strategies in RRMS
Please login below to download this issue (PDF)